| 翻訳と辞書 |
febuxostat
Febuxostat (INN; trade names Adenuric in Europe and New Zealand, Uloric in the US, Goturic in Latin America, Feburic in Japan) is a drug that inhibits xanthine oxidase, thus reducing production of uric acid in the body. It is used in the treatment of chronic gout and hyperuricemia.
Febuxostat was discovered by scientists at the Japanese pharmaceutical company Teijin in 1998. Teijin partnered the drug with TAP Pharmaceuticals in the US and Ipsen in Europe. Ipsen obtained marketing approval for febuxostat from the European Medicines Agency in April 2008, Takeda obtained FDA approval in February 2009, and Teijin obtained approval from the Japanese "Pharmaceuticals and Medical Devices Agency" in 2011.
==Medical uses ==
Febuxostat is used to treat chronic gout and hyperuricemia.〔 National Institute for Health and Clinical Excellence concluded that febuxostat is more effective than standard doses of allopurinol, but not more effective than higher doses of allopurinol.〔(Febuxostat for the management of hyperuricaemia in people with gout (TA164) Chapter 4. Consideration of the evidence )〕
Febuxostat is in the US pregnancy category C; there are no adequate and well-controlled studies in pregnant women.〔
抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』
■ウィキペディアで「febuxostat」の詳細全文を読む
スポンサード リンク
| 翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|